April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Anterior migration of Dexamethasone intravitreal implants: how to manage with these complications?
Author Affiliations & Notes
  • Vincent Fortoul
    Croix-Rousse University Hospital, Lyon, France
  • Laurent Kodjikian
    Croix-Rousse University Hospital, Lyon, France
  • Philippe Denis
    Croix-Rousse University Hospital, Lyon, France
  • Footnotes
    Commercial Relationships Vincent Fortoul, None; Laurent Kodjikian, None; Philippe Denis, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1793. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Vincent Fortoul, Laurent Kodjikian, Philippe Denis; Anterior migration of Dexamethasone intravitreal implants: how to manage with these complications?. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1793.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate and describe the risks factors, ocular complications, and the different managements strategies when an anterior migration of dexamethasone (DEX) intravitreal implant (Ozurdex®; Allergan, Inc., Irvine, CA) occurred. We also propose 2 simples’ decision trees to prevent and to manage these complications.

Methods: A retrospective study to analyze the main cases (n=15) of anterior migration of DEX intravitreal implant since 2010 until November 2013. The researches have been made with PubMed database. Only articles in English and French were used.

Results: 15 cases (15 eyes) of anterior migration of DEX intravitreal implant were reported in PubMed database. The mean age was 55.3 years (SD±21,09). The mean delay when an anterior migration occured was 16.3 days (range:1-40 days). DEX implant was indicated for macular edema after BRVO (13.3%; n=2), CRVO (33%; n=5), Irvine-Gass syndrome (26.7%; n=4), and non-infectious uveitis (26.7%; n=4). 80% (n=12) of eyes were pseudophakic, 20% (n=3) were aphakic. 93.3% (n=14) of the eyes had no posterior lens capsule. A previous pars plana vitrectomy was reported for 73.3% (n=11) of the eyes. 33.3% (n=5) of the patients were supported with simples postural management. Only 1 of these patients required a secondary surgical extraction of the DEX implant, after an early re-migration at 48h. 46.7% (n=7) required a primary surgical extraction, 13.3% (n=2) a surgical integration in the vitreous humor, and 6.7% (n=1) a Nd-YAG Laser fragmentation. Finally, 73.3% (n=11) of the eyes presented an important endothelial corneal decompensation more than 1 month after management of the anterior migration. Among these eyes, 45% (n=5) required a corneal transplantation. No significant differences ((p>0.05) were noted between the two main management strategies (postural or primary surgical) for permanent corneal edema risk.

Conclusions: We defined different risks factors (aphakic or pseudophakic status when there is no posterior lens capsule, in vitrectomized or not vitrectomized eyes) that must be known in clinical practice to prevent an anterior migration of DEX intravitreal implant. Permanent corneal edema is the main complication after anterior migration.

Keywords: 464 clinical (human) or epidemiologic studies: risk factor assessment • 763 vitreous • 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×